Activated Charcoal Apis Mellifera Artemisia Cina P

證據等級: L5

預測適應症: 0 個

Multi-ingredient Homeopathic Combination: Insufficient Data for TxGNN Evaluation

One-Sentence Summary

This candidate is a 15-ingredient homeopathic combination product — including activated charcoal, bee venom (Apis mellifera), and botanical/mineral extracts — that is not currently marketed in Taiwan and carries no approved indication on record. The TxGNN model was unable to generate any repurposing predictions for this compound, most likely because none of its ingredients could be matched to a DrugBank node in the knowledge graph. Without a mapped drug identity or a predicted target disease, a standard drug repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Drug Identifier	15-ingredient combination (no single INN, no DrugBank ID)
Original Indication	None on record
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only) — effectively below L5: no prediction was generated
Taiwan Market Status	Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN knowledge graph maps each candidate drug to a DrugBank node, then traverses disease-association edges to score novel indications. This pipeline requires at minimum one resolvable DrugBank ID.

This candidate presents three compounding obstacles:

No DrugBank ID available. The drugbank_id field is null, and the query log confirms that even though the DrugBank source returned a result count of 1, no ID was recorded — suggesting the match was ambiguous or returned a partial/unlinked record.
Homeopathic and botanical ingredients. Most of the 15 components (Apis mellifera, Pulsatilla montana, Sepia officinalis, Veratrum album, etc.) are homeopathic or crude botanical preparations that are either absent from the DrugBank small-molecule database or appear only as nutraceutical entries without pharmacological targets.
Multi-ingredient complexity. The combination has no unified mechanism of action. Each ingredient would require independent mapping, and combination-level synergy predictions are outside TxGNN’s current model scope.

Until a reliable DrugBank anchor is established for at least the pharmacologically active ingredients (e.g., activated charcoal, potassium alum), the knowledge graph cannot propagate a prediction score.

Taiwan Market Information

This drug has zero active licenses in Taiwan and is not marketed. No authorization table can be generated.

Safety Considerations

Please refer to the package insert for safety information.

Note: Individual ingredients carry distinct safety profiles. Activated charcoal can adsorb co-administered medications; Veratrum album contains veratrum alkaloids with narrow therapeutic indices; Delphinium staphisagria contains delphinine, a cardiotoxic alkaloid. Any future clinical evaluation should treat these ingredients separately rather than as a unified safety entity.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN produced no repurposing candidates because the drug cannot be resolved to a knowledge graph node, and no original indication or existing evidence base exists to support a manual hypothesis either.

To proceed, the following is needed:

Resolve DrugBank identity — manually verify which (if any) of the 15 ingredients maps to an active DrugBank small-molecule entry; activated charcoal (DB01882) and sodium chloride (DB09154) are directly identifiable and could serve as anchors for a narrowed query.
Clarify intended therapeutic indication — determine the clinical context in which this combination was formulated; without this, neither a repurposing hypothesis nor a comparator trial can be identified.
Evaluate ingredient-by-ingredient — run TxGNN predictions for pharmacologically tractable individual components (e.g., activated charcoal for gastrointestinal or toxicological indications) rather than the mixture as a whole.
Assess regulatory pathway — as a homeopathic combination not registered in Taiwan, any development path would require engagement with TFDA’s special review track for traditional/complementary medicines before standard NDA repurposing analysis applies.
Safety dossier for active botanicals — commission a full toxicology review for Veratrum album root and Delphinium staphisagria seed before any human study is considered.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.